Uracil Mustard

CHEMBL1488 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

252.1 g/mol

LogP

0.5

Phase

4

Uracil mustard is an alkylating antineoplastic agent that combines a uracil base with a nitrogen mustard moiety, enabling it to cross-link DNA strands and inhibit DNA replication in rapidly proliferating cancer cells. It was used orally for treatment of chronic lymphocytic leukemia, non-Hodgkin lymphoma, and other hematologic malignancies, as well as certain solid tumors including breast cancer. It has largely been replaced by more targeted therapies but served as an important early oral alkylating agent.

Berat Molekul

252,0900 g/mol

LogP

0,50

TPSA

61,40 Å²

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Oc1ncc(N(CCCl)CCCl)c(O)n1

InChI

InChI=1S/C8H11Cl2N3O2/c9-1-3-13(4-2-10)6-5-11-8(15)12-7(6)14/h5H,1-4H2,(H2,11,12,14,15)

Molecular Formula

C8H11Cl2N3O2

HBD / HBA

2 / 3

Ikatan yang Dapat Dirotasi

5

Atom Berat

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Uracil mustard is an alkylating antineoplastic agent that combines a uracil base with a nitrogen mustard moiety, enabling it to cross-link DNA strands and inhibit DNA replication in rapidly proliferating cancer cells. It was used orally for treatment of chronic lymphocytic leukemia, non-Hodgkin lymphoma, and other hematologic malignancies, as well as certain solid tumors including breast cancer. It has largely been replaced by more targeted therapies but served as an important early oral alkylating agent.

Yes, Uracil Mustard is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1488. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6194. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Uracil Mustard di PillFYI

Struktur

Data Cepat

Rumus: C8H11Cl2N3O2

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.